Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran

(Length of Discussion: 14 min)

Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer.

Biographies:
Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School

Alicia Morgans, MD, MPH

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe